MiMedx Group (MDXG) Set to Release Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG) is projected to announce its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of $0.0003 per share and revenue of $68.56 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. The firm had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. On average, analysts expect MiMedx Group to post ($0.10) EPS for the current fiscal year and $0.04 EPS for the next fiscal year.

MiMedx Group Price Performance

Shares of MDXG stock opened at $3.91 on Monday. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.97. The firm has a market cap of $569.92 million, a PE ratio of 97.77 and a beta of 1.18. The stock has a 50 day moving average of $4.53 and a 200-day moving average of $4.08. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07.

Analyst Upgrades and Downgrades

MDXG has been the topic of a number of research reports. Wall Street Zen raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings upgraded shares of MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 27th. Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a report on Monday, August 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of MiMedx Group in a research report on Tuesday, September 15th. Finally, Craig Hallum increased their target price on shares of MiMedx Group from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, MiMedx Group presently has an average rating of “Moderate Buy” and a consensus price target of $8.57.

MiMedx Group Company Profile

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.